Comparison of in vitro and in vivo effects of prazosin on lipid metabolism.
The results of an in vitro study indicate that only nonselective and alpha 2-blocking agents are capable of increasing adrenergic-stimulated lipolysis in human adipose tissue. Concentrations in vivo of total triglycerides, total cholesterol, and low-density lipoprotein and very low-density lipoprotein cholesterol did not change with prazosin treatment. It is suggested that the low affinity of prazosin for the cyclase-coupled alpha 2 receptors in human adipose tissue explains the lack of effect of prazosin on lipid mobilization from tissue to blood and the absence of a change in low-density lipoprotein and very low-density lipoprotein cholesterol in vivo. However, there was a significant increase in high-density lipoprotein cholesterol. The prazosin-related increase in the cholesterol ratio in vivo has been interpreted as a beneficial modification of this risk factor, but is not explained by our in vitro observations.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects* / Q000201:enzymology; D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D014280:Triglycerides; D002784:Cholesterol; D000262:Adenylyl Cyclases; D011224:Prazosin